poisar

Stocks · News reference

Guggenheim Maintains Buy on Illumina, Raises Price Target to $226

BenzingaJul 31, 2026, 2:01 PMBenzinga Newsdesk

Guggenheim analyst Subbu Nambi maintains Illumina (NASDAQ:ILMN) with a Buy and raises the price target from $200 to $226.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Jul 31, 2026, 2:01 PM
Checked
Jul 31, 2026, 2:01 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncAug 7, 2026, 9:56 AMResearchandmarkets.Com

    Precision Medicine Collaboration and Licensing Deals 2019-2026 | Gain Access to Over 1,350 Deals and Benchmark with Confidence

    ResearchAndMarkets.com released a comprehensive report analyzing 1,350+ precision medicine collaboration and licensing deals from 2019-2026. The report provides detailed benchmarking data on deal structures, financial terms, and contract provisions to support business development and strategy decisions in the precision medicine sector.

    Read original at globenewswire-inc